ASK REDCHAT ANYTHING ABOUT LARIMAR THERAPEUTICS INC.
Larimar Therapeutics Inc. (NASDAQ: LRMR)
Listen to this Section
$3.57
-0.0650
(
-1.79% )
984.0K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Nomlabofusp (CTI-1601)DetailsRare genetic disease, Rare diseases, Friedreich’s Ataxia |
Phase 2 |
| Nomlabofusp (CTI-1601)DetailsRare diseases, Rare genetic disease, Friedreich’s Ataxia |
Phase 2 |
Market Data
|
| Open |
$3.57 |
| Previous Close |
$3.63 |
| Volume |
984.0K |
| Market Cap |
$377.10M |
| Day Range |
$3.56 - $4.08 |
| 52 Week Range |
$2.72 - $6.42 |
| Shares Outstanding |
103.88M |
| Change % |
-1.79% |
| Net Change |
▼ -0.0650 |
| Insider Ownership |
-0.01% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2020 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
4,627,968.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-01-19 |
Sale |
-31250.00 |
Celano Michael |
| 2024-01-19 |
Sale |
-22500.00 |
Clayton Russell |
| 2024-01-19 |
Sale |
-66125.00 |
BEN-MAIMON CAROLE |
| 2023-12-08 |
Buy |
5000.00 |
Shankar Gopi |
| 2023-10-05 |
Sale |
-16600.00 |
SHERMAN JEFFREY W |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 8-k |
8K-related |
63 |
Nov 10, 2025 |
| 10-q |
Quarterly Reports |
56 |
Nov 05, 2025 |
| 8-k |
8K-related |
13 |
Nov 05, 2025 |
| 8-k |
8K-related |
63 |
Oct 14, 2025 |
| 8-k |
8K-related |
33 |
Sep 29, 2025 |
| 8-k |
8K-related |
72 |
Aug 14, 2025 |
| 10-q |
Quarterly Reports |
56 |
Aug 14, 2025 |
| 4 |
Insider transactions |
2 |
Aug 04, 2025 |
| 8-k |
8K-related |
15 |
Jul 31, 2025 |
| 8-k |
8K-related |
12 |
Jul 29, 2025 |